Brief: Lava Therapeutics Highlights Encouraging Clinical Updates On Lead Program, Lava-051, In Chronic Lymphocytic Leukemia And Multiple Myeloma Patients
16/06/2022 21:34
June 16 (Reuters) - LAVA Therapeutics NV LVTX.O :
* LAVA THERAPEUTICS HIGHLIGHTS ENCOURAGING CLINICAL UPDATES
ON
LEAD PROGRAM, LAVA-051, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND
MULTIPLE MYELOMA PATIENTS
Source text for Eikon: ID:nGNX4ZkgPk
Further company coverage: LVTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LAVA Therapeutics NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:29 PM
Brief: Xoma Royalty Announces Closing Of Transactions To Acquire Lava Therapeutics N.V.
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM